Among them, the interaction of the programmed death receptor-1 (PD-1) with its cognate ligands PD-L1 or PD-L2 represents a crucial pathway to evade immune recognition in all kinds of tumor entities including TNBC. Here, PDCD1LG2 is linked to neoplasm.